Clinical Research Papers:

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival

Shuhua Yi _, Dehui Zou, Chengwen Li, Shizhen Zhong, Weiwei Chen, Zengjun Li, Wenjie Xiong, Wei Liu, Enbin Liu, Rui Cui, Kun Ru, Peihong Zhang, Yan Xu, Gang An, Rui Lv, Junyuan Qi, Jianxiang Wang, Tao Cheng and Lugui Qiu

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:42362-42371. https://doi.org/10.18632/oncotarget.5705

Metrics: PDF 1623 views  |   HTML 1911 views  |   ?  


Shuhua Yi1,*, Dehui Zou1,*, Chengwen Li1, Shizhen Zhong1, Weiwei Chen1, Zengjun Li1, Wenjie Xiong1, Wei Liu1, Enbin Liu1, Rui Cui1,2, Kun Ru1, Peihong Zhang1, Yan Xu1, Gang An1, Rui Lv1, Junyuan Qi1, Jianxiang Wang1, Tao Cheng1, Lugui Qiu1

1State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

2Department of Hematology, Tianjin First Center Hospital, Tianjin, China

*These authors have contributed equally to this work

Correspondence to:

Lugui Qiu, e-mail: [email protected]

Keywords: mantle cell lymphoma, MYC, BCL2, P53, prognosis

Received: May 09, 2015     Accepted: October 13, 2015     Published: October 23, 2015


The incidence and prognostic role of MYC and BCL2 rearrangements in mature B-cell lymphomas have been extensively studied, except the infrequent mantle cell lymphoma (MCL). Here, we analyzed the MYC and BCL2 abnormalities and other cytogenetic aberrations by fluorescence in situ hybridization (FISH) in 50 MCL patients with bone marrow involvement. Eighteen patients (36.0%) had MYC gains and/or amplifications, and twelve patients (24.0%) had BCL2 gains and/or amplifications. Among the 18 patients with MYC abnormality, four had simultaneous MYC translocations, but no BCL2 translocation was detected among patients with BCL2 abnormality. Only two patients (4.0%) had both MYC and BCL2 abnormalities. The patients with a MYC abnormality had a significantly higher tumor burden, a higher percentage of medium/high risk MIPI group and genomic instability compared to those without this abnormality. However, no significant difference was observed between patients with or without a BCL2 abnormality in terms of clinical and cytogenetic factors. Patients with a MYC abnormality had poorer progress-free survival (PFS) (9.0 vs. 48.0 months, p = .000) and overall survival (OS) (12.0 vs. 94.5 months, p = .000), but the presence of a BCL2 abnormality did not significantly influence either PFS or OS. In multivariate analysis, the MYC abnormality was the independent adverse factor for both PFS and OS, and intensive chemotherapy did not improve the outcome of these patients. Thus, the presence of a MYC but not BCL2 abnormality predicted the poor survival of MCL patients, and a new treatment strategy should be developed for these patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5705